Donanemab – what we know about the latest Alzheimer’s drug
Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...
Northwest Arkansas Democrat Gazette24m
Arkansas group suggests ways to improve care for Alzheimer’s, dementia patients
Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...
STAT1d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
Yahoo19h
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund donanemab - the ...
National Institute for Health and Care Excellence1d
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
BMJ1d
NICE rejects Alzheimer’s drug donanemab owing to cost and “significant health risks”
The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...
Second ‘game-changing’ Alzheimer’s drug donanemab gets green light in UK – but WON’T be available on NHS
A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Outsourcing-pharma1d
NICE rejects Donanemab for NHS use despite MHRA approval
Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...